Mizoribine: A New Approach in the Treatment of Renal Disease

Table 1

Changes in serum MZB concentration and AVC0-4 in the 11 patients who received oral MZB pulse therapy.

Case	Serum MZB concentration (𝜇g/mL)						AUC0-4 (𝜇g⋅h/mL)
	C0	C1	C2	C3	C4	C24
1	0.0	2.8	4.5	2.9	2.1	0.0	12.3
2	0.0	1.4	2.2	4.2	3.4	0.0	11.2
3	0.0	1.8	3.5	4.4	3.9	0.0	13.6
4	0.0	1.7	2.5	3.8	1.9	0.0	9.9
5	0.0	4.1	5.1	3.9	2.9	0.0	16.0
6	0.0	1.2	3.0	4.2	4.9	0.0	13.3
7	0.0	2.2	3.8	3.6	2.5	0.0	12.1
8	0.0	2.2	2.7	3.0	2.5	0.0	10.4
9	0.0	1.4	2.7	3.3	2.4	0.0	9.8
10	0.0	1.4	2.5	2.6	2.0	0.0	8.5
11	0.0	1.6	1.8	2.2	1.4	0.0	7.0

Serum MZB was measured immediately before the morning dose of MZB (C0) and 1 hour (Cl), 2 hours (C2), 3 hours (C3), 4 hours (C4), and 24 hours (C24) after the dose.
AUC = area under the concentration-time curve; MZB = mizoribine.